PUBLISHER: Persistence Market Research | PRODUCT CODE: 2026099

PUBLISHER: Persistence Market Research | PRODUCT CODE: 2026099

Immunoassay Interference Blocker Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2032

PUBLISHED: April 23, 2026

PAGES: 193 Pages

DELIVERY TIME: 2-5 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Persistence Market Research has recently released a comprehensive report on the global Immunoassay Interference Blocker Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

Immunoassay Interference Blocker Market Size (2025E): US$ 342.7 Mn
Projected Market Value (2032F): US$ 507.4 Mn
Global Market Growth Rate (CAGR 2025 to 2032): 5.8%

Immunoassay Interference Blocker Market - Report Scope:

The immunoassay interference blocker market comprises specialized reagents and compounds used to eliminate or minimize assay interference caused by endogenous substances such as heterophilic antibodies, human anti-animal antibodies, and other interfering agents. These blockers are essential in improving the accuracy, sensitivity, and reliability of immunoassay-based diagnostic tests, including ELISA, chemiluminescent assays, and lateral flow assays. Increasing reliance on immunoassays in clinical diagnostics, biotechnology research, and pharmaceutical development is significantly contributing to market growth.

Market Growth Drivers:

Several key factors are fueling the growth of the global immunoassay interference blocker market. The rising demand for highly accurate diagnostic testing, especially in the detection of chronic and infectious diseases, has increased the need for reliable immunoassay performance. Growing adoption of immunoassays in clinical laboratories and hospitals, coupled with advancements in biotechnology and life sciences research, is driving the use of interference blockers. Additionally, the expansion of personalized medicine and biomarker-based diagnostics is further accelerating demand for high-precision assay solutions.

Market Restraints:

Despite its steady growth, the immunoassay interference blocker market faces certain challenges. High costs associated with advanced reagents and assay optimization can limit adoption, particularly in cost-sensitive healthcare settings. Limited awareness regarding assay interference issues in developing regions may hinder market penetration. Furthermore, variability in assay conditions and lack of standardization across laboratories can affect the consistent performance of interference blockers, posing a challenge for manufacturers.

Market Opportunities:

The immunoassay interference blocker market presents promising opportunities driven by increasing research and development activities in diagnostics and biopharmaceuticals. The growing focus on improving diagnostic accuracy and reducing false-positive and false-negative results is creating demand for advanced blocking solutions. Emerging markets in Asia-Pacific and Latin America offer untapped potential due to expanding healthcare infrastructure and rising investments in laboratory technologies. Moreover, technological advancements and innovation in assay design and reagent development are expected to open new avenues for market expansion.

Key Questions Answered in the Report:

What are the primary factors driving the global immunoassay interference blocker market's growth?
Which regions and market segments are experiencing the highest demand for immunoassay interference blockers?
How are advancements in diagnostic technologies influencing market dynamics?
Who are the key players in the immunoassay interference blocker market, and what strategies are they adopting to stay competitive?
What are the emerging trends and future projections for the global immunoassay interference blocker market?

Competitive Intelligence and Business Strategy:

Leading companies in the global immunoassay interference blocker market are focusing on product innovation, strategic collaborations, and expanding their research capabilities to maintain a competitive edge. These companies are investing in the development of advanced reagents that enhance assay accuracy and reduce interference-related errors. Partnerships with diagnostic laboratories, research institutes, and pharmaceutical companies are enabling broader application of interference blockers. Additionally, companies are strengthening their global distribution networks and focusing on quality assurance to ensure consistent product performance.

Companies Covered in This Report:

F. Hoffmann-La Roche Ltd.
Merck KGaA
Meridian Bioscience, Inc.
Scantibodies Laboratory, Inc.
Thermo Fisher Scientific Inc.
Rockland Immunochemicals, Inc.
Biopanda Diagnostics
Molecular Depot LLC
TOYOBO.inc.
Abcam plc
Aviva Systems Biology Corporation
Bio-Rad Laboratories Inc.
Candor
Diagnopal
Surmodics, Inc.
Biosensis Pty Ltd.
Creative Biolabs
Fapon Biotech Inc.

Market Segmentation

By Product

Antibody Interference Blockers
Detection Interference Blockers
Surface Interference Blockers

By Technique

ELISA
Lateral Flow Assay
Western Blotting
Chemiluminescent Immunoassay (CLIA)
Latex Agglutination Turbidimetric Immunoassay (LTIA)
Others

By End-User

Biotechnology Companies
Contract Research Organizations
Academic & Research Institutes
Clinical Labs and Hospitals

By Region

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Product Code: PMRREP24343

1. Executive Summary

1.1. Global Immunoassay Interference Blocker Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025 - 2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Global Healthcare Spending Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.3.3. Global Research and Development Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Product Adoption Analysis
3.2. Recent Product Launches
3.3. Regulatory Landscape
3.4. Value Chain Analysis
3.5. PESTLE Analysis
3.6. Porter's Five Force Analysis
3.7. Promotional Strategies, By Key Players
3.8. Parent Market Overview

4. Global Immunoassay Interference Blocker Market Outlook: Historical (2019 - 2024) and Forecast (2025 - 2032)

4.1. Key Highlights
- 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
- 4.2.2. Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global Immunoassay Interference Blocker Market Outlook: Product
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019 - 2024
- 4.3.3. Market Size (US$ Mn) Analysis and Forecast, By Product, 2025 - 2032
  - 4.3.3.1. Antibody Interference Blocker
    - 4.3.3.1.1. Serum Derived Blocker
    - 4.3.3.1.2. Heterophilic Blocking Reagents
    - 4.3.3.1.3. Human Immunoglobulin Blocker
    - 4.3.3.1.4. Animal Monoclonal Antibody IgG Blocker
    - 4.3.3.1.5. Animal Polyclonal Antibody IgG Blocker
    - 4.3.3.1.6. Others
  - 4.3.3.2. Detection Interference Blocker
    - 4.3.3.2.1. Enzyme Blocker
    - 4.3.3.2.1.1. Alkaline Phosphatase Blocker
    - 4.3.3.2.1.2. B-Galactosidase Blocker
    - 4.3.3.2.1.3. Other Enzyme Blocker
    - 4.3.3.2.2. Others
  - 4.3.3.3. Surface Interference Blocker
    - 4.3.3.3.1. Bovine Serum Albumin Blocker
    - 4.3.3.3.2. Peptide Based Blocker
    - 4.3.3.3.3. Others
- 4.3.4. Market Attractiveness Analysis: Product
4.4. Global Immunoassay Interference Blocker Market Outlook: Technique
- 4.4.1. Introduction / Key Findings
- 4.4.2. Historical Market Size (US$ Mn) Analysis, By Technique, 2019 - 2024
- 4.4.3. Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025 - 2032
  - 4.4.3.1. ELISA
    - 4.4.3.1.1. Sandwich Immunoassay
    - 4.4.3.1.2. Antibody Detection Assay
    - 4.4.3.1.3. Competitive Assay
  - 4.4.3.2. Lateral Flow
  - 4.4.3.3. Western Blotting
  - 4.4.3.4. Chemiluminescent Immunoassay (CLIA)
  - 4.4.3.5. Latex Agglutination Turbidimetric Immunoassay (LTIA)
  - 4.4.3.6. Others
- 4.4.4. Market Attractiveness Analysis: Technique
4.5. Global Immunoassay Interference Blocker Market Outlook: End-user
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Mn) Analysis, By End-user, 2019 - 2024
- 4.5.3. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025 - 2032
  - 4.5.3.1. Biotechnology Companies
  - 4.5.3.2. Contract Research Organizations
  - 4.5.3.3. Academic & Research Institutes
  - 4.5.3.4. Clinical Labs and Hospitals
- 4.5.4. Market Attractiveness Analysis: End-user

5. Global Immunoassay Interference Blocker Market Outlook: Region

5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019 - 2024
5.3. Market Size (US$ Mn) Analysis and Forecast, By Region, 2025 - 2032
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. East Asia
- 5.3.4. South Asia and Oceania
- 5.3.5. Latin America
- 5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region

6. North America Immunoassay Interference Blocker Market Outlook

6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
- 6.2.1. By Country
- 6.2.2. By Product
- 6.2.3. By Technique
- 6.2.4. By End-user
6.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
- 6.3.1. U.S.
- 6.3.2. Canada
6.4. Market Size (US$ Mn) Analysis and Forecast, By Product, 2025 - 2032
- 6.4.1. Antibody Interference Blocker
  - 6.4.1.1. Serum Derived Blocker
  - 6.4.1.2. Heterophilic Blocking Reagents
  - 6.4.1.3. Human Immunoglobulin Blocker
  - 6.4.1.4. Animal Monoclonal Antibody IgG Blocker
  - 6.4.1.5. Animal Polyclonal Antibody IgG Blocker
  - 6.4.1.6. Others
- 6.4.2. Detection Interference Blocker
  - 6.4.2.1. Enzyme Blocker
    - 6.4.2.1.1. Alkaline Phosphatase Blocker
    - 6.4.2.1.2. B-Galactosidase Blocker
    - 6.4.2.1.3. Other Enzyme Blocker
  - 6.4.2.2. Others
- 6.4.3. Surface Interference Blocker
  - 6.4.3.1. Bovine Serum Albumin Blocker
  - 6.4.3.2. Peptide Based Blocker
  - 6.4.3.3. Others
6.5. Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025 - 2032
- 6.5.1. ELISA
  - 6.5.1.1. Sandwich Immunoassay
  - 6.5.1.2. Antibody Detection Assay
  - 6.5.1.3. Competitive Assay
- 6.5.2. Lateral Flow
- 6.5.3. Western Blotting
- 6.5.4. Chemiluminescent Immunoassay (CLIA)
- 6.5.5. Latex Agglutination Turbidimetric Immunoassay (LTIA)
- 6.5.6. Others
6.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025 - 2032
- 6.6.1. Biotechnology Companies
- 6.6.2. Contract Research Organizations
- 6.6.3. Academic & Research Institutes
- 6.6.4. Clinical Labs and Hospitals
6.7. Market Attractiveness Analysis

7. Europe Immunoassay Interference Blocker Market Outlook

7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
- 7.2.1. By Country
- 7.2.2. By Product
- 7.2.3. By Technique
- 7.2.4. By End-user
7.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Russia
- 7.3.7. Rest of Europe
7.4. Market Size (US$ Mn) Analysis and Forecast, By Product, 2025 - 2032
- 7.4.1. Antibody Interference Blocker
  - 7.4.1.1. Serum Derived Blocker
  - 7.4.1.2. Heterophilic Blocking Reagents
  - 7.4.1.3. Human Immunoglobulin Blocker
  - 7.4.1.4. Animal Monoclonal Antibody IgG Blocker
  - 7.4.1.5. Animal Polyclonal Antibody IgG Blocker
  - 7.4.1.6. Others
- 7.4.2. Detection Interference Blocker
  - 7.4.2.1. Enzyme Blocker
    - 7.4.2.1.1. Alkaline Phosphatase Blocker
    - 7.4.2.1.2. B-Galactosidase Blocker
    - 7.4.2.1.3. Other Enzyme Blocker
  - 7.4.2.2. Others
- 7.4.3. Surface Interference Blocker
  - 7.4.3.1. Bovine Serum Albumin Blocker
  - 7.4.3.2. Peptide Based Blocker
  - 7.4.3.3. Others
7.5. Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025 - 2032
- 7.5.1. ELISA
  - 7.5.1.1. Sandwich Immunoassay
  - 7.5.1.2. Antibody Detection Assay
  - 7.5.1.3. Competitive Assay
- 7.5.2. Lateral Flow
- 7.5.3. Western Blotting
- 7.5.4. Chemiluminescent Immunoassay (CLIA)
- 7.5.5. Latex Agglutination Turbidimetric Immunoassay (LTIA)
- 7.5.6. Others
7.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025 - 2032
- 7.6.1. Biotechnology Companies
- 7.6.2. Contract Research Organizations
- 7.6.3. Academic & Research Institutes
- 7.6.4. Clinical Labs and Hospitals
7.7. Market Attractiveness Analysis

8. East Asia Immunoassay Interference Blocker Market Outlook

8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
- 8.2.1. By Country
- 8.2.2. By Product
- 8.2.3. By Technique
- 8.2.4. By End-user
8.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
8.4. Market Size (US$ Mn) Analysis and Forecast, By Product, 2025 - 2032
- 8.4.1. Antibody Interference Blocker
  - 8.4.1.1. Serum Derived Blocker
  - 8.4.1.2. Heterophilic Blocking Reagents
  - 8.4.1.3. Human Immunoglobulin Blocker
  - 8.4.1.4. Animal Monoclonal Antibody IgG Blocker
  - 8.4.1.5. Animal Polyclonal Antibody IgG Blocker
  - 8.4.1.6. Others
- 8.4.2. Detection Interference Blocker
  - 8.4.2.1. Enzyme Blocker
    - 8.4.2.1.1. Alkaline Phosphatase Blocker
    - 8.4.2.1.2. B-Galactosidase Blocker
    - 8.4.2.1.3. Other Enzyme Blocker
  - 8.4.2.2. Others
- 8.4.3. Surface Interference Blocker
  - 8.4.3.1. Bovine Serum Albumin Blocker
  - 8.4.3.2. Peptide Based Blocker
  - 8.4.3.3. Others
8.5. Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025 - 2032
- 8.5.1. ELISA
  - 8.5.1.1. Sandwich Immunoassay
  - 8.5.1.2. Antibody Detection Assay
  - 8.5.1.3. Competitive Assay
- 8.5.2. Lateral Flow
- 8.5.3. Western Blotting
- 8.5.4. Chemiluminescent Immunoassay (CLIA)
- 8.5.5. Latex Agglutination Turbidimetric Immunoassay (LTIA)
- 8.5.6. Others
8.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025 - 2032
- 8.6.1. Biotechnology Companies
- 8.6.2. Contract Research Organizations
- 8.6.3. Academic & Research Institutes
- 8.6.4. Clinical Labs and Hospitals
8.7. Market Attractiveness Analysis

9. South Asia & Oceania Immunoassay Interference Blocker Market Outlook

9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
- 9.2.1. By Country
- 9.2.2. By Product
- 9.2.3. By Technique
- 9.2.4. By End-user
9.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
- 9.3.1. India
- 9.3.2. Southeast Asia
- 9.3.3. ANZ
- 9.3.4. Rest of South Asia & Oceania
9.4. Market Size (US$ Mn) Analysis and Forecast, By Product, 2025 - 2032
- 9.4.1. Antibody Interference Blocker
  - 9.4.1.1. Serum Derived Blocker
  - 9.4.1.2. Heterophilic Blocking Reagents
  - 9.4.1.3. Human Immunoglobulin Blocker
  - 9.4.1.4. Animal Monoclonal Antibody IgG Blocker
  - 9.4.1.5. Animal Polyclonal Antibody IgG Blocker
  - 9.4.1.6. Others
- 9.4.2. Detection Interference Blocker
  - 9.4.2.1. Enzyme Blocker
    - 9.4.2.1.1. Alkaline Phosphatase Blocker
    - 9.4.2.1.2. B-Galactosidase Blocker
    - 9.4.2.1.3. Other Enzyme Blocker
  - 9.4.2.2. Others
- 9.4.3. Surface Interference Blocker
  - 9.4.3.1. Bovine Serum Albumin Blocker
  - 9.4.3.2. Peptide Based Blocker
  - 9.4.3.3. Others
9.5. Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025 - 2032
- 9.5.1. ELISA
  - 9.5.1.1. Sandwich Immunoassay
  - 9.5.1.2. Antibody Detection Assay
  - 9.5.1.3. Competitive Assay
- 9.5.2. Lateral Flow
- 9.5.3. Western Blotting
- 9.5.4. Chemiluminescent Immunoassay (CLIA)
- 9.5.5. Latex Agglutination Turbidimetric Immunoassay (LTIA)
- 9.5.6. Others
9.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025 - 2032
- 9.6.1. Biotechnology Companies
- 9.6.2. Contract Research Organizations
- 9.6.3. Academic & Research Institutes
- 9.6.4. Clinical Labs and Hospitals
9.7. Market Attractiveness Analysis

10. Latin America Immunoassay Interference Blocker Market Outlook

10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
- 10.2.1. By Country
- 10.2.2. By Product
- 10.2.3. By Technique
- 10.2.4. By End-user
10.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
- 10.3.1. Brazil
- 10.3.2. Mexico
- 10.3.3. Rest of Latin America
10.4. Market Size (US$ Mn) Analysis and Forecast, By Product, 2025 - 2032
- 10.4.1. Antibody Interference Blocker
  - 10.4.1.1. Serum Derived Blocker
  - 10.4.1.2. Heterophilic Blocking Reagents
  - 10.4.1.3. Human Immunoglobulin Blocker
  - 10.4.1.4. Animal Monoclonal Antibody IgG Blocker
  - 10.4.1.5. Animal Polyclonal Antibody IgG Blocker
  - 10.4.1.6. Others
- 10.4.2. Detection Interference Blocker
  - 10.4.2.1. Enzyme Blocker
    - 10.4.2.1.1. Alkaline Phosphatase Blocker
    - 10.4.2.1.2. B-Galactosidase Blocker
    - 10.4.2.1.3. Other Enzyme Blocker
  - 10.4.2.2. Others
- 10.4.3. Surface Interference Blocker
  - 10.4.3.1. Bovine Serum Albumin Blocker
  - 10.4.3.2. Peptide Based Blocker
  - 10.4.3.3. Others
10.5. Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025 - 2032
- 10.5.1. ELISA
  - 10.5.1.1. Sandwich Immunoassay
  - 10.5.1.2. Antibody Detection Assay
  - 10.5.1.3. Competitive Assay
- 10.5.2. Lateral Flow
- 10.5.3. Western Blotting
- 10.5.4. Chemiluminescent Immunoassay (CLIA)
- 10.5.5. Latex Agglutination Turbidimetric Immunoassay (LTIA)
- 10.5.6. Others
10.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025 - 2032
- 10.6.1. Biotechnology Companies
- 10.6.2. Contract Research Organizations
- 10.6.3. Academic & Research Institutes
- 10.6.4. Clinical Labs and Hospitals
10.7. Market Attractiveness Analysis

11. Middle East & Africa Immunoassay Interference Blocker Market Outlook

11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2024
- 11.2.1. By Country
- 11.2.2. By Product
- 11.2.3. By Technique
- 11.2.4. By End-user
11.3. Market Size (US$ Mn) Analysis and Forecast, By Country, 2025 - 2032
- 11.3.1. GCC Countries
- 11.3.2. Egypt
- 11.3.3. South Africa
- 11.3.4. Northern Africa
- 11.3.5. Rest of Middle East & Africa
11.4. Market Size (US$ Mn) Analysis and Forecast, By Product, 2025 - 2032
- 11.4.1. Antibody Interference Blocker
  - 11.4.1.1. Serum Derived Blocker
  - 11.4.1.2. Heterophilic Blocking Reagents
  - 11.4.1.3. Human Immunoglobulin Blocker
  - 11.4.1.4. Animal Monoclonal Antibody IgG Blocker
  - 11.4.1.5. Animal Polyclonal Antibody IgG Blocker
  - 11.4.1.6. Others
- 11.4.2. Detection Interference Blocker
  - 11.4.2.1. Enzyme Blocker
    - 11.4.2.1.1. Alkaline Phosphatase Blocker
    - 11.4.2.1.2. B-Galactosidase Blocker
    - 11.4.2.1.3. Other Enzyme Blocker
  - 11.4.2.2. Others
- 11.4.3. Surface Interference Blocker
  - 11.4.3.1. Bovine Serum Albumin Blocker
  - 11.4.3.2. Peptide Based Blocker
  - 11.4.3.3. Others
11.5. Market Size (US$ Mn) Analysis and Forecast, By Technique, 2025 - 2032
- 11.5.1. ELISA
  - 11.5.1.1. Sandwich Immunoassay
  - 11.5.1.2. Antibody Detection Assay
  - 11.5.1.3. Competitive Assay
- 11.5.2. Lateral Flow
- 11.5.3. Western Blotting
- 11.5.4. Chemiluminescent Immunoassay (CLIA)
- 11.5.5. Latex Agglutination Turbidimetric Immunoassay (LTIA)
- 11.5.6. Others
11.6. Market Size (US$ Mn) Analysis and Forecast, By End-user, 2025 - 2032
- 11.6.1. Biotechnology Companies
- 11.6.2. Contract Research Organizations
- 11.6.3. Academic & Research Institutes
- 11.6.4. Clinical Labs and Hospitals
11.7. Market Attractiveness Analysis

12. Competition Landscape

12.1. Market Share Analysis, 2024
12.2. Market Structure
- 12.2.1. Competition Intensity Mapping By Market
- 12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 12.3.1. Thermo Fisher Scientific Inc.
  - 12.3.1.1. Overview
  - 12.3.1.2. Segments and Products
  - 12.3.1.3. Key Financials
  - 12.3.1.4. Market Developments
  - 12.3.1.5. Market Strategy
- 12.3.2. Merck KGaA
- 12.3.3. Meridian Bioscience, Inc.
- 12.3.4. F. Hoffmann-La Roche Ltd
- 12.3.5. Biopanda Diagnostics
- 12.3.6. Molecular Depot LLC
- 12.3.7. TOYOBO.inc.
- 12.3.8. Abcam plc
- 12.3.9. Aviva Systems Biology Corporation
- 12.3.10. Bio-Rad Laboratories Inc.
- 12.3.11. Candor
- 12.3.12. Diagnopal
- 12.3.13. Scantibodies Laboratory, Inc.
- 12.3.14. Surmodics, Inc.
- 12.3.15. Biosensis Pty Ltd
- 12.3.16. Rockland Immunochemicals, Inc.
- 12.3.17. Creative Biolabs
- 12.3.18. Fapon Biotech Inc.

13. Appendix

13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ